Treat Early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection

AIDS Patient Care and STDs

Volumn 23, Issue 9, 2009, Pages 715-725

  Wagner, Glenn ^a   Ryan, Gery ^a   Osilla, Karen Chan ^a   Bhatti, Laveeza ^b   Goetz, Matthew ^c   Witt, Mallory ^d  

^a RAND CORPORATION   (United States)

^b AIDS HEALTHCARE FOUNDATION   (United States)

^c Greater Los Angeles Veterans Hospital   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; FEMALE; GENOTYPE; HEALTH CARE PERSONNEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIXED INFECTION; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; SEMI STRUCTURED INTERVIEW; SUBSTANCE ABUSE;

ANTIVIRAL AGENTS; DECISION MAKING; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LOS ANGELES; MENTAL DISORDERS; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349218308     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0049     Document Type: Article

References (47)

1. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-497.
3. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008;47:1128-1135.
4. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS 2008;22:1979-1991.
5. Moreno A, Diz S, Moreno L, et al. Histological findings, predictors of severe fibrosis, and assessment of factors with effect on the fibrosis progression rate in HIV-infected patients with chronic hepatitis C in the era of HAART [Abstract 1056]. 15th CROI. Boston, MA: February 3-6, 2008.
6. Rauch A, Egger M, Reichen J, et al. Chronic hepatitis C in HIV-infected patients: Low eligibility and applicability of therapy with pegylated- interferon-alpha plus ribavirin. J Acquir Immune Defic Syndr 2005;38:238-240.
7. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immnunoDeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003;36:97-100.
8. Taylor LE, Costello T, Alt E, et al. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV= hepatitis C virus co-infected individuals. AIDS 2002;16: 1700-1701.
9. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003;36:1039-1046.
10. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005;100:1772-1779.
11. Adeyemi OM, Jensen D, Attar B, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDs 2004;18:239-245.
12. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2006;24: 585-591.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterfeon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;29: 438-450.
14. Chung RT, Andersen J, Volberding P, et al. Peginterfeon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
15. Perrone C, Carrat F, Banisadr F, et al. ANRS HC02RIBAVIC: a randomised controlled trial of pegylated interferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin as primary treatment of chronic hepatitis C in HIVcoinfected patients. Hepatology 2002;36:283A.
16. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV=HCV co-infected patients. AIDS 2004;18:F27-F36.
17. Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDs 2008;22:449-457.
18. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002;347:975-982.
19. Bräu N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV=HCV-co-infection with interferon a-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004;39:989-998.
20. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV=hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004;18:75-79.
21. Soriano V, Barreiro P, Martin-Carbonero L, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007;9:99-113. (Pubitemid 47177082)
22. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C. Gastroenterology 2002;123:2082-2099.
23. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
24. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
25. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV=hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008;47: 36-49.
26. Valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV=Hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008;47:50-55.
27. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006;57:570-572.
28. Cacoub P, Rosenthal E, Halfon P, et al. Treatment of hepatitis C virus and uman immunodeficiency virus coinfection: From large trials to real life. J Viral Hepat 2006;13:678-682.
29. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451.
30. Huckans MS, Loftis JM, Blackwell AD, Linke A, Hauser P. Interferon alpha therapy for hepatitis C: Treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy 2007;2:4.
31. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and=or substance use disorders. J Viral Hepatol 2006;13:235-241.
32. Cawthorne CH, Rudar KR, Bruton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-155.
33. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.
34. Moody DL, Sindre G, Brasethvik T, Solvberg A. Evaluating the quality of process models: Empirical testing of a quality framework. Lect Notes Comput Sci 2003;2503:380-396.
35. Conjeevaram H, Fried M, Jeffers L, et al. Peginterferon and ribavirin treatment in African American patients and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477. (Pubitemid 44142464)
36. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol. 2004;99:1160-1174.
37. Vento S, Di Perri G, Cruciani M, et al. Rapid decline of CD4+ cells after IFN treatment in HIV-1 infection. Lancet 1993;341:958-959.
38. Tedaldi E, Baker RK, Moorman AC, et al. Influence of coinfected with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36: 363-367.
39. Wong JB, Bennet WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-2093.
40. Mehta S, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33:126-133.
41. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193.
42. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. European Addition Research 2002;8:45-49.
43. Cullen R, Khan N, Sanjeev A, et al. Depression and sustained virologic response in hepatitis C patients [Abstract V-1898]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
44. Dieperink E, Ho S, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon -alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-112.
45. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA 2001;285:1003-1005.
46. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36:S210-219.
47. Adeyemi OM, Jensen D, Attar B, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDs 2004;18:239-245.